Back to results
US 7,993,656 B2Granted
Modified clostridial toxins with enhanced translocation capabilities and altered targeting activity for clostridial toxin target cells
AssigneeAllergan, Inc.
InventorsLance E. Steward, Joseph Francis, Ester G. Fernandez-Salas, Marcella A. Gilmore, Shengwen Li, Kei Roger Aoki
Life of this patent
Estimating the term…
Abstract
The invention provides modified Clostridial toxins comprising a Clostridial toxin enzymatic domain, a Clostridial toxin translocation domain, a translocation facilitating domain and an altered target domain; polynucleotide molecules encoding such modified Clostridial toxins; and methods of producing such modified Clostridial toxins.
Claims5
A modified Clostridial toxin comprising:
- a) a Clostridial toxin enzymatic domain that executes an enzymatic target modification step of a Clostridial toxin intoxication process;
- b) a Clostridial toxin translocation domain that executes a translocation step of a Clostridial toxin intoxication process;
- c) a translocation facilitating domain that facilitates a translocation step of a Clostridial toxin intoxication process, wherein the translocation facilitating domain is a Clostridial toxin translocation facilitating domain or an enveloped virus fusogenic peptide domain;
- d) an altered targeting domain that selectively binds to a non-Clostridial toxin receptor present on a Clostridial toxin target cell and executes a cell binding step of a Clostridial toxin intoxication process, wherein the altered targeting domain is a glucagon like hormone peptide that selectively binds to a glucagon like hormone receptor;
- and
- e) a protease cleavage site;
- wherein cleavage of the protease cleavage site converts the single-chain form of the modified Clostridial toxin into the di-chain form.
4 more elements
Dependencies are inferred from the claim text.